Clinical trial · Interventional
A Pilot Study Evaluating Oral Triamcinalone in Patients With Androgen Independent Prostate Cancer
NCT00186108CI-TRIAL-00000799completedPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The primary purpose of this study is to evaluate the ability of oral triamcinalone given twice a day to patients with androgen independent prostate cancer to produce a sustained biochemical response. Secondary goals are to describe the safety and tolerability at this dose and schedule, to determine the time to sustained biochemical response, to determine the duration of biochemical response, to determine the time to disease progression.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Oral Triamcinalone | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Ability of oral triamcinalone given twice a day to patients with androgen independent prostate cancer to produce a sustained biochemical response.
- timeFrame
- Following treatment
Secondary outcomes (1)
- measure
- Safety and tolerability at this dose and schedule, time to sustained biochemical response, duration of biochemical response, time to disease progression
- timeFrame
- Following treatment
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * 18 years of age and older * Histologically documented adenocarcinoma of prostate * Currently receiving LHRH agonists with castrate levels of testosterone or who have had an orchiectomy * Must have had a rise in PSA despite anti androgen withdrawal * Exhibit 2 consecutive rise in PSA after the last hormonal manipulation * Minimum PSA of greater than 5 KPS greater than 80% * Normal cortisol level at entry * Life expectancy greater than 6 months * Provide written consent pursuant to regulatory requirements prior to initiation of study procedure Exclusion criteria: * Younger than 18 years * Patients without prostate cancer
References
Publications (0)
Data not yet available
No reference posted for this study.